PL EN


Preferences help
enabled [disable] Abstract
Number of results
2007 | 54 | 4 | 831-838
Article title

Metabolic transformations of antitumor imidazoacridinone, C-1311, with microsomal fractions of rat and human liver

Content
Title variants
Languages of publication
EN
Abstracts
EN
The imidazoacridinone derivative C-1311 is an antitumor agent in Phase II clinical trials. The molecular mechanism of enzymatic oxidation of this compound in a peroxidase model system was reported earlier. The present studies were performed to elucidate the role of rat and human liver enzymes in metabolic transformations of this drug. C-1311 was incubated with different fractions of liver cells and the reaction mixtures were analyzed by RP-HPLC. We showed that the drug was more sensitive to metabolism with microsomes than with cytosol or S9 fraction of rat liver cells. Incubation of C-1311 with microsomes revealed the presence of four metabolites. Their structures were identified as dealkylation product, M0, as well as a dimer-like molecule, M1. Furthermore, we speculate that the hydroxyl group was most likely substituted in metabolite M3. It is of note that a higher rate of transformation was observed for rat than for human microsomes. However, the differences in metabolite amounts were specific for each metabolite. The reactivity of C-1311 with rat microsomes overexpressing P450 isoenzymes, of CYP3A and CYP4A families was higher than that with CYP1A and CYP2B. Moreover, the M1 metabolite was selectively formed with CYP3A, whereas M3 with CYP4A. In conclusion, this study revealed that C-1311 varied in susceptibility to metabolic transformation in rat and human cells and showed selectivity in the metabolism with P450 isoenzymes. The obtained results could be useful for preparing the schedule of individual directed therapy with C-1311 in future patients.
Publisher

Year
Volume
54
Issue
4
Pages
831-838
Physical description
Dates
published
2007
received
2007-08-20
revised
2007-11-28
accepted
2007-12-03
(unknown)
2007-12-17
Contributors
  • Department of Pharmaceutical Technology and Biochemistry, Gdańsk University of Technology, Gdańsk, Poland
  • Department of Pharmaceutical Technology and Biochemistry, Gdańsk University of Technology, Gdańsk, Poland
  • Department of Analytical Chemistry, Chemical Faculty, Gdańsk University of Technology, Gdańsk, Poland
author
  • Department of Pharmaceutical Technology and Biochemistry, Gdańsk University of Technology, Gdańsk, Poland
  • Department of Pharmaceutical Technology and Biochemistry, Gdańsk University of Technology, Gdańsk, Poland
References
  • Augustin E, Wheatley DN, Lamb J, Konopa J (1996) Imidazoacridinones arrest cell cycle progression in the G2 phase of L1210 cells. Cancer Chemother Pharmacol 38: 39-44.
  • Berger B, Marquardt H, Westendorf J (1996) Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents. Cancer Res 56: 2094-2104.
  • Burger AM, Double JA, Konopa J, Bibby MC (1996) Preclinical evaluation of novel imidazoacridone derivatives with potent activity against experimental colorectal cancer. Brit J Cancer 74: 1369-1374.
  • Calabrese CR, Loadman PM, Lim LSE, Bibby MC, Double JA, Brown JE, Lamb JH (1999) In vivo metabolism of the antitumor imidazoacridinone C1311 in the mouse and in vitro comparison with humans. Drug Metab Dispos 27: 240-245.
  • Constantino L, Rosa E, Iley J (1992) The microsomal demethylation of N,N‑dimethylbenzamides. Substituent and kinetic deuterium isotope effects. Biochem Pharmacol 44: 651-658.
  • Cholody WM, Martelli S, Lukowicz J, Konopa J (1990) 5‑((Aminoalkyl)amino]-imidazo(4,5,1-de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity. J Med Chem 33: 49-52.
  • Cholody WM, Martelli S, Konopa J (1992) Chromophore-modified antineoplastic imidazoacridinones. Synthesis and activity against murine leukemias. J Med Chem 35: 378-382.
  • Cholody WM, Horowska B, Martelli S, Konopa J (1996) Structure-activity relationship for antineoplastic imidazoacridinones: Synthesis and antileukemic activity in vivo. J Med Chem 39: 1028-1032.
  • De Jong FA, De Jonge MJA, Verweij J, Mathijssen RHJ (2006) Role of pharmacogenetics in irinotecan therapy. Cancer Lett 234: 90-106.
  • Deeken JF, Figg WD, Bates SE, Sparreboom A (2007) Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anti-Cancer Drugs 18: 111-126.
  • Dzięgielewski J, Konopa J (1998) Characterization of covalent binding to DNA of antitumor imidazoacridinone C-1311, after metabolic activation. Ann Oncol 9 (Suppl 1) Abstr. 137.
  • Dzięgielewski J, Ślusarski B, Konitz A, Składanowski A, Konopa J (2002) Intercalation of imidazoacridinones to DNA and its relevance to cytotoxic and antitumor activity. Biochem Pharmacol 63: 1653-1662.
  • Favretto D, Bertazzo A, Costa CVL, Allegri G, Donato N, Traldi P (1998) The role of peroxidase in the oligomerization of 5-hydroxytryptamine investigated by matrix-assisted laser desorption/ionisation mass spectrometry. Rap Comm Mass Spectrom 12: 193-97.
  • Guengerich FP (1990) Enzymatic oxidation of xenobiotic chemicals. Crit Rev Biochem Mol Biol 25: 97-153.
  • Guengerich FP (1995) Human cytochrome P450 enzymes. In Cytochrome P450. Structure, Mechanism and Biochemistry, Ortiz de Montellano PR, ed, pp 473-536. Plenum Press, New York.
  • Gustavson DL, Long ME, Bradshaw EL, Merz AL, Kerzic PJ (2005) P450 induction alters paclitaxel pharmacokinetics and tissue distribution with multiple dosing. Cancer Chemother Pharmacol 56: 248-254.
  • Hariparsad N, Sane RS, Strom SC, Desai PB (2006) In vitro methods in human drug biotransformation research: Implications for cancer chemotherapy. Toxicol in Vitro 20: 135‑153.
  • Husbeck B, Powis G (2002) The redox protein thioredoxin-1 regulates the constitutive and inducible expression of the estrogen metabolizing cytochromes P450 1B1 and 1A1 in MCF‑7 human breast cancer cells. Carcinogenesis 23: 1625-1630.
  • Hyzy M, Bozko P, Konopa J, Skladanowski A (2005) Antitumour imidazoacridinone C-1311 induces cell death by mitotic catastrophe in human colon carcinoma cells. Biochem Pharmacol 69: 801-809.
  • Lamb J, Wheatley DN (1996) Cell killing by novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations and coincident with dose-differentiated cell cycle perturbation. Brit J Cancer 74: 1359-1368.
  • Mani C, Gelboin HV, Park SS, Pearce R, Parkinson A, Kupfer D (1993) Metabolism of the antimammary cancer antiestrogenic agent tamoxifen 1. Cytochrome P-450-catalysed N‑demethylation and 4-hydroxylation. Drug Metab Dispos 21: 645-656.
  • Mazerska Z, Dziegielewski J, Konopa J (2001) Enzymatic activation of a new antitumor drug, 5‑diethylaminoethylamino-8-hydroxyimidazoacridinone, C‑1311, observed after its intercalation into DNA. Biochem Pharmacol 61: 685-694.
  • Mazerska Z, Zamponi S, Marassi R, Sowiński P, Konopa J (2002) The products of electro- and photochemical oxidation of 2-hydroxyacridinone, the reference compound of antitumor imidazoacridinone drivatives. J Electroanal Chem 521: 144-154.
  • Mazerska Z, Sowinski P, Konopa J (2003) Molecular mechanism of the enzymatic oxidation investigated for imidazoacridinone antitumor drug, C-1311. Biochem Pharmacol 66: 1727-1736.
  • Mazerska Z (2003) Similarity between enzymatic and electrochemical oxidation of 2‑hydroxyacridinone, the reference compound of antitumor imidazoacridinones. Acta Biochim Polon 50: 515-525.
  • Michon T, Chenu M, Kellershon N, Desmadril M, Gueguen J (1997) Horseradish peroxidase oxidation of tyrosine-containing peptides and their subsequent polymerisation: a kinetic study. Biochemistry 36: 8504-8513.
  • Murray GI (2000) The role of cytochrome P450 in tumor development and progression and its potential therapy. J Pathol 192: 419-426.
  • Oyama T, Kagawa N, Kunugita N (2004) Expression of cytochrome P450 in tumor tissues and its association with cancer development. Front Biosci 9: 1967-1976.
  • Osborne CK. (1998) Tamoxifen in the treatment of breast cancer. N Engl J Med 339: 1609-1618.
  • Skladanowski A, Plisov SY, Konopa J, Larsen KL (1996) Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol Pharmacol 49: 772-780.
  • Zaffaroni N, De Marco C, Villa R, Riboldi S, Daidone MG, Double JA (2001) Cell growth inhibition, G2M cell cycle arrest and apoptosis induced by the imidazoacridinone C1311 in human tumour cell lines. Eur J Cancer 37: 1953-1962.
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.bwnjournal-article-abpv54p831kz
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.